Shanghai Henlius Biotech, Inc. is a global biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of biologic medicines. Established in 2010 and headquartered in Shanghai, the company operates with a vision to provide high-quality, affordable, and innovative biopharmaceutical therapies to patients worldwide. Its primary areas of focus include oncology, autoimmune diseases, and ophthalmic diseases, supporting a broad product portfolio spanning monoclonal antibodies, antibody-drug conjugates, fusion proteins, and small molecules. Henlius has launched multiple products in major and emerging markets, including first-in-class and biosimilar therapies such as anti-PD-1 and anti-HER2 monoclonal antibodies. The company’s commitment to global regulatory standards is reflected in its manufacturing facilities, which are certified by authorities in China, the EU, and the United States. With a substantial research pipeline of approximately 50 molecules and a strong emphasis on immuno-oncology and combination therapies, Henlius plays a significant role in advancing access to cutting-edge treatments and shaping the landscape of biotechnology innovation both domestically and internationally.